Sean R Tunis1,2,3, Lara J Maxwell4,5,6, Ian D Graham1,2,3, Beverley J Shea1,2,3, Dorcas E Beaton1,2,3, Clifton O Bingham1,2,3, Peter Brooks1,2,3, Philip G Conaghan1,2,3, Maria Antonietta D'Agostino1,2,3, Maarten P de Wit1,2,3, Laure Gossec1,2,3, Lyn M March1,2,3, Lee S Simon1,2,3, Jasvinder A Singh1,2,3, Vibeke Strand1,2,3, George A Wells1,2,3, Peter Tugwell1,2,3. 1. From the Center for Medical Technology Policy; Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland; University of Alabama at Birmingham and Birmingham Veterans Affairs Medical Center, Birmingham, Alabama; SDG LLC, Cambridge, Massachusetts; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; Centre for Practice-Changing Research, Ottawa Hospital Research Institute; Ottawa Hospital Research Institute, Clinical Epidemiology Program; School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa; Cardiovascular Research Methods Centre, University of Ottawa Heart Institute; Department of Epidemiology and Community Medicine, University of Ottawa; Department of Medicine, Faculty of Medicine, University of Ottawa; Cochrane Musculoskeletal, University of Ottawa, Ottawa; Musculoskeletal Health and Outcomes Research, St. Michael's Hospital; Institute for Work and Health; Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute and the Institute for Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; Centre for Health Policy, Melbourne School of Population and Global Health, University of Melbourne, Melbourne; Sydney Medical School, Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, St. Leonards, Australia; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK; Hôpital Ambroise Paré, Rheumatology Department, Boulogne-Billancourt; INSERM U1173, Laboratoire d'Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University, Montigny-le-Bretonneux; Sorbonne Universités, UPMC Univ Paris 06; AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Department of Medical Humanities, VU University Medical Centre/EMGO+ Institute, Amsterdam, the Netherlands. 2. IDG is a recipient of a Canadian Institutes of Health Research (CIHR) Foundation Grant Scheme (RFN #143237), focused on understanding the process and effect of integrated knowledge translation. COB has received funding from a Eugene Washington Engagement Award (EIAN 1988) from the Patient Centered Outcomes Research Institute (PCORI). All statements and views expressed in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of PCORI, its board of governors, or methodology committee; or the UK National Health Service, the NIHR, or the Department of Health; or the position or policy of the US Department of Veterans Affairs or the US government. PGC is funded in part by the NIHR Leeds Musculoskeletal Biomedical Research Unit. This article presents independent research funded by the NIHR. JAS has received research grants from Takeda and Savient, and consultant fees from Takeda and the American College of Rheumatology. JAS serves as the principal investigator for an investigator-initiated study funded by Horizon pharmaceuticals through a grant to DINORA Inc., a 501 (c)(3) entity. 3. S.R. Tunis, MD, MSc, President and CEO, Center for Medical Technology Policy; L.J. Maxwell, PhD, Cochrane Musculoskeletal, University of Ottawa and Centre for Practice-Changing Research, Ottawa Hospital Research Institute; I.D. Graham, PhD, School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program; B.J. Shea, PhD, School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program; D.E. Beaton, BScOT, PhD, Musculoskeletal Health and Outcomes Research, St. Michael's Hospital, and Institute for Work and Health, and Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute and the Institute for Health Policy Management and Evaluation, University of Toronto; C.O. Bingham III, MD, Division of Rheumatology, Department of Medicine, Johns Hopkins University; P. Brooks, MD, FRACP, Centre for Health Policy, Melbourne School of Population and Global Health, University of Melbourne; P.G. Conaghan, MD, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit; M.A. D'Agostino, MD, PhD, APHP, Hôpital Ambroise Paré, Rheumatology Department, and INSERM U1173, Laboratoire d'Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University; M.P. de Wit, PhD, Patient Research Partner, Department of Medical Humanities, VU University Medical Centre/EMGO+ Institute; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; L.M. March, MBBS, PhD, Liggins Professor of Rheumatology and Musculoskeletal Epidemiology, Sydney Medical School, Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital; L.S. Simon, MD, Co-managing Director of SDG LLC; J.A. Singh, MD, MPH, Professor of Medicine and Epidemiology, University of Alabama at Birmingham, and Staff Physician, Birmingham Veterans Affairs Medical Center; V. Strand, MD, Adjunct Clinical Professor, Division of Immunology/Rheumatology, Stanford University School of Medicine; G.A. Wells, MSc, PhD, Director, Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, and Professor, Department of Epidemiology and Community Medicine, University of Ottawa; P. Tugwell, MD, MSc, Department of Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program, and School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa. 4. From the Center for Medical Technology Policy; Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland; University of Alabama at Birmingham and Birmingham Veterans Affairs Medical Center, Birmingham, Alabama; SDG LLC, Cambridge, Massachusetts; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; Centre for Practice-Changing Research, Ottawa Hospital Research Institute; Ottawa Hospital Research Institute, Clinical Epidemiology Program; School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa; Cardiovascular Research Methods Centre, University of Ottawa Heart Institute; Department of Epidemiology and Community Medicine, University of Ottawa; Department of Medicine, Faculty of Medicine, University of Ottawa; Cochrane Musculoskeletal, University of Ottawa, Ottawa; Musculoskeletal Health and Outcomes Research, St. Michael's Hospital; Institute for Work and Health; Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute and the Institute for Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada; Centre for Health Policy, Melbourne School of Population and Global Health, University of Melbourne, Melbourne; Sydney Medical School, Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, St. Leonards, Australia; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK; Hôpital Ambroise Paré, Rheumatology Department, Boulogne-Billancourt; INSERM U1173, Laboratoire d'Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University, Montigny-le-Bretonneux; Sorbonne Universités, UPMC Univ Paris 06; AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Department of Medical Humanities, VU University Medical Centre/EMGO+ Institute, Amsterdam, the Netherlands. lmaxwell@uottawa.ca. 5. IDG is a recipient of a Canadian Institutes of Health Research (CIHR) Foundation Grant Scheme (RFN #143237), focused on understanding the process and effect of integrated knowledge translation. COB has received funding from a Eugene Washington Engagement Award (EIAN 1988) from the Patient Centered Outcomes Research Institute (PCORI). All statements and views expressed in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of PCORI, its board of governors, or methodology committee; or the UK National Health Service, the NIHR, or the Department of Health; or the position or policy of the US Department of Veterans Affairs or the US government. PGC is funded in part by the NIHR Leeds Musculoskeletal Biomedical Research Unit. This article presents independent research funded by the NIHR. JAS has received research grants from Takeda and Savient, and consultant fees from Takeda and the American College of Rheumatology. JAS serves as the principal investigator for an investigator-initiated study funded by Horizon pharmaceuticals through a grant to DINORA Inc., a 501 (c)(3) entity. lmaxwell@uottawa.ca. 6. S.R. Tunis, MD, MSc, President and CEO, Center for Medical Technology Policy; L.J. Maxwell, PhD, Cochrane Musculoskeletal, University of Ottawa and Centre for Practice-Changing Research, Ottawa Hospital Research Institute; I.D. Graham, PhD, School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program; B.J. Shea, PhD, School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program; D.E. Beaton, BScOT, PhD, Musculoskeletal Health and Outcomes Research, St. Michael's Hospital, and Institute for Work and Health, and Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute and the Institute for Health Policy Management and Evaluation, University of Toronto; C.O. Bingham III, MD, Division of Rheumatology, Department of Medicine, Johns Hopkins University; P. Brooks, MD, FRACP, Centre for Health Policy, Melbourne School of Population and Global Health, University of Melbourne; P.G. Conaghan, MD, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit; M.A. D'Agostino, MD, PhD, APHP, Hôpital Ambroise Paré, Rheumatology Department, and INSERM U1173, Laboratoire d'Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University; M.P. de Wit, PhD, Patient Research Partner, Department of Medical Humanities, VU University Medical Centre/EMGO+ Institute; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; L.M. March, MBBS, PhD, Liggins Professor of Rheumatology and Musculoskeletal Epidemiology, Sydney Medical School, Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital; L.S. Simon, MD, Co-managing Director of SDG LLC; J.A. Singh, MD, MPH, Professor of Medicine and Epidemiology, University of Alabama at Birmingham, and Staff Physician, Birmingham Veterans Affairs Medical Center; V. Strand, MD, Adjunct Clinical Professor, Division of Immunology/Rheumatology, Stanford University School of Medicine; G.A. Wells, MSc, PhD, Director, Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, and Professor, Department of Epidemiology and Community Medicine, University of Ottawa; P. Tugwell, MD, MSc, Department of Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program, and School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa. lmaxwell@uottawa.ca.
Abstract
OBJECTIVE: While there has been substantial progress in the development of core outcomes sets, the degree to which these are used by researchers is variable. We convened a special workshop on knowledge translation at the Outcome Measures in Rheumatology (OMERACT) 2016 with 2 main goals. The first focused on the development of a formal knowledge translation framework and the second on promoting uptake of recommended core outcome domain and instrument sets. METHODS: We invited all 189 OMERACT 2016 attendees to the workshop; 86 attended, representing patient research partners (n = 15), healthcare providers/clinician researchers (n = 52), industry (n = 4), regulatory agencies (n = 4), and OMERACT fellows (n = 11). Participants were given an introduction to knowledge translation and were asked to propose and discuss recommendations for the OMERACT community to (1) strengthen stakeholder involvement in the core outcome instrument set development process, and (2) promote uptake of core outcome sets with a specific focus on the potential role of post-regulatory decision makers. RESULTS: We developed the novel "OMERACT integrated knowledge translation" framework, which formalizes OMERACT's knowledge translation strategies. We produced strategies to improve stakeholder engagement throughout the process of core outcome set development and created a list of creative and innovative ways to promote the uptake of OMERACT's core outcome sets. CONCLUSION: The guidance provided in this paper is preliminary and is based on the views of the participants. Future work will engage OMERACT groups, "post-regulatory decision makers," and a broad range of different stakeholders to identify and evaluate the most useful methods and processes, and to revise guidance accordingly.
OBJECTIVE: While there has been substantial progress in the development of core outcomes sets, the degree to which these are used by researchers is variable. We convened a special workshop on knowledge translation at the Outcome Measures in Rheumatology (OMERACT) 2016 with 2 main goals. The first focused on the development of a formal knowledge translation framework and the second on promoting uptake of recommended core outcome domain and instrument sets. METHODS: We invited all 189 OMERACT 2016 attendees to the workshop; 86 attended, representing patient research partners (n = 15), healthcare providers/clinician researchers (n = 52), industry (n = 4), regulatory agencies (n = 4), and OMERACT fellows (n = 11). Participants were given an introduction to knowledge translation and were asked to propose and discuss recommendations for the OMERACT community to (1) strengthen stakeholder involvement in the core outcome instrument set development process, and (2) promote uptake of core outcome sets with a specific focus on the potential role of post-regulatory decision makers. RESULTS: We developed the novel "OMERACT integrated knowledge translation" framework, which formalizes OMERACT's knowledge translation strategies. We produced strategies to improve stakeholder engagement throughout the process of core outcome set development and created a list of creative and innovative ways to promote the uptake of OMERACT's core outcome sets. CONCLUSION: The guidance provided in this paper is preliminary and is based on the views of the participants. Future work will engage OMERACT groups, "post-regulatory decision makers," and a broad range of different stakeholders to identify and evaluate the most useful methods and processes, and to revise guidance accordingly.
Entities:
Keywords:
ARTHRITIS; OUTCOME ASSESSMENT; RHEUMATOLOGY; TRANSLATIONAL MEDICAL RESEARCH
Authors: Allison Tong; Braden Manns; Angela Yee Moon Wang; Brenda Hemmelgarn; David C Wheeler; John Gill; Peter Tugwell; Robert Pecoits-Filho; Sally Crowe; Tess Harris; Wim Van Biesen; Wolfgang C Winkelmayer; Adeera Levin; Aliza Thompson; Vlado Perkovic; Angela Ju; Talia Gutman; Amelie Bernier-Jean; Andrea K Viecelli; Emma O'Lone; Jenny Shen; Michelle A Josephson; Yeoungjee Cho; David W Johnson; Bénédicte Sautenet; Marcello Tonelli; Jonathan C Craig Journal: Kidney Int Date: 2018-10-22 Impact factor: 10.612
Authors: Allison Tong; Sally Crowe; John S Gill; Tess Harris; Brenda R Hemmelgarn; Braden Manns; Roberto Pecoits-Filho; Peter Tugwell; Wim van Biesen; Angela Yee Moon Wang; David C Wheeler; Wolfgang C Winkelmayer; Talia Gutman; Angela Ju; Emma O'Lone; Benedicte Sautenet; Andrea Viecelli; Jonathan C Craig Journal: BMJ Open Date: 2018-04-20 Impact factor: 2.692
Authors: Jamie J Kirkham; Sarah Gorst; Douglas G Altman; Jane M Blazeby; Mike Clarke; Sean Tunis; Paula R Williamson Journal: Trials Date: 2019-02-11 Impact factor: 2.279
Authors: Maarten de Wit; Cyrus Cooper; Peter Tugwell; Nathalie Bere; John Kirwan; Philip G Conaghan; Charlotte Roberts; Isabelle Aujoulat; Nasser Al-Daghri; Islene Araujo de Carvalho; Mary Barker; Nicola Bedlington; Maria Luisa Brandi; Olivier Bruyère; Nansa Burlet; Philippe Halbout; Mickaël Hiligsmann; Famida Jiwa; John A Kanis; Andrea Laslop; Wendy Lawrence; Daniel Pinto; Concepción Prieto Yerro; Véronique Rabenda; René Rizzoli; Marieke Scholte-Voshaar; Mila Vlaskovska; Jean-Yves Reginster Journal: Aging Clin Exp Res Date: 2019-04-16 Impact factor: 3.636
Authors: Eithne Heffernan; Dylan Keegan; Jenny Mc Sharry; Tomás Barry; Peter Tugwell; Andrew W Murphy; Conor Deasy; David Menzies; Cathal O'Donnell; Siobhan Masterson Journal: Resusc Plus Date: 2022-01-10